Essay
Assume a patient has a rare disease. The only known option for treatment at this stage of the disease is an experimental drug which costs $200,000 and has been clinically proven to provide a life expectancy gain of 2 months. Why would the patient's insurance company be likely to deny the pre-certification for the treatment? Why would it be difficult to convince a patient's family that a third round of an experimental treatment might only add at most two months of life expectancy at a cost of $200,000 and would not be economically efficient?
Correct Answer:

Verified
Our tendency is to do something rather t...View Answer
Unlock this answer now
Get Access to more Verified Answers free of charge
Correct Answer:
Verified
View Answer
Unlock this answer now
Get Access to more Verified Answers free of charge
Q20: Physician office management solutions to reducing the
Q21: Health economists view all incentives as monetary
Q22: Dr. Getzen remarks that care and information
Q23: Comment on the following statement. The net
Q24: According to the 2001 study by Cutler
Q25: Comment on the expected trends in the
Q26: Economics is the science which studies how
Q27: Behavioral economics studies the decision making by
Q29: Path dependence is the sociologist's way of
Q30: Suppose health economists are able to quantify